Erlotinib-related keratopathy in a patient underwent laser in situ keratomileusis.
Erlotinib is a tyrosine kinase inhibitor of the epidermal growth factor receptor. Since there is a wide expression of the epidermal growth factor receptors in the epithelial tissues of ocular surface and adnexa, ocular adverse reactions may happen during systemic administration of erlotinib. Previously reported ocular adverse reactions of erlotinib include trichomegaly, periorbital rash, ectropion, blepharitis, persistent corneal epithelial defect, corneal ulcer and perforation. We report the first case of erlotinib-related keratopathy in a patient who had received laser in situ keratomileusis. The patient presented a special picture of flap striae related to erlotinib. Improvement of keratopathy after cessation of erlotinib was demonstrated.
a Department of Ophthalmology , Koo Foundation Sun Yat-Sen Cancer Center , Taipei , Taiwan and.
Hui-Chuan
HC
Kau
b Department of Ophthalmology , Taipei Veterans General Hospital and National Yang Ming University , Taipei , Taiwan.
Chieh-Chih
CC
Tsai
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology; D000077192:Adenocarcinoma of Lung; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D003316:Corneal Diseases / Q000139:chemically induced*; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D000069347:Erlotinib Hydrochloride / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D020731:Keratomileusis, Laser In Situ; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D013125:Spinal Neoplasms / Q000188:drug therapy / Q000556:secondary
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000069347:Erlotinib Hydrochloride; C512478:EGFR protein, human; D066246:ErbB Receptors
Erlotinib; flap striae; keratopathy; laser in situ keratomileusis